Abstract | OBJECTIVES: To determine the effectiveness of nitric oxide agents in modifying the metabolic factors of pre-eclampsia and its effectiveness in preventing the onset of pre-eclampsia in high-risk pregnancies. INTRODUCTION: INCLUSION CRITERIA: This review will consider randomized controlled trials that compare nitric oxide donors and precursors with a placebo or no intervention on pregnant women (18 to 44 years) with ≤ 20-week gestational age that are at high risk of pre-eclampsia. The primary outcome of interest will be the onset of pre-eclampsia. Secondary outcomes include increased systolic and diastolic blood pressure, elevated asymmetric dimethylarginine levels, decreased endothelial nitric oxide synthase activity, reduced maternal placental vasculature, and abnormal Doppler ultrasound waveforms. METHODS: Data sources will be drawn up from MEDLINE, CINAHL, ProQuest (Health and Medicine), and Web of Science from inception till current date. No language restrictions will be applied in the search strategy. Selected studies will be assessed against the JBI critical appraisal checklist, and the certainty of evidence and strength of recommendations from findings will also be ascertained. SYSTEMATIC REVIEW REGISTRATION NUMBER: PROSPERO CRD42018099298.
|
Authors | Daniel A Nnate, Mzwandile Mabhala, Alan Massey |
Journal | JBI evidence synthesis
(JBI Evid Synth)
Vol. 18
Issue 12
Pg. 2658-2665
(12 2020)
ISSN: 2689-8381 [Electronic] United States |
PMID | 32813424
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 JBI. |
Chemical References |
- Vasodilator Agents
- Nitric Oxide
|
Topics |
- Adolescent
- Adult
- Female
- Humans
- Nitric Oxide
(therapeutic use)
- Placenta
(drug effects)
- Pre-Eclampsia
(prevention & control)
- Pregnancy
- Pregnancy, High-Risk
(metabolism)
- Systematic Reviews as Topic
- Vasodilator Agents
(therapeutic use)
|